EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY 4.0

Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants

Ralf Gold, Krzysztof W Selmaj iD, Regina Berkovich, Jeffrey A Cohen, Giancarlo Comi, Eva K Havrdová, James K Sheffield, Hetal Desai, Chun-Yen Cheng, Jon V Riolo, Andrew Thorpe, Erik DeBoer und 1 weitere

Annals of Clinical and Translational Neurology · 2026

DOI: 10.1002/acn3.70366 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Annals of Clinical and Translational Neurology, 2026. Verfasst von Ralf Gold und 12 weiteren Autor:innen. Beteiligte Einrichtung: Neurologische Universitätsklinik, St. Josef Hospital, Bochum, Germany. Hauptthemen laut MEDLINE: Indans, Multiple Sclerosis, Relapsing-Remitting, Oxadiazoles, Sphingosine 1 Phosphate Receptor Modulators. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bristol Myers Squibb, Bristol-Myers Squibb Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Return of disease activity is expected when patients discontinue disease‐modifying therapy (DMT) for multiple sclerosis (MS). Some MS DMTs are associated with higher‐than‐expected disease activity (rebound) after discontinuation. This exploratory analysis assessed disease activity and risk of rebound after ozanimod discontinuation.

Methods

DAYBREAK (NCT02576717; October 2015–April 2023) was a single‐arm, open‐label extension trial of ozanimod 0.92 mg/d in participants with relapsing MS who completed phase 1–3 ozanimod trials. Two protocol amendments increased the required safety follow‐up from an initial 28 days to 75 and then 90 days. Confirmed post‐treatment relapses were characterized.

Results

Of 2494 participants, 1679 participants had ≥ 1 day of follow‐up and did not initiate commercial ozanimod in ≤ 14 days of exiting the trial; 30.6% had ≤ 60 days of post‐treatment follow‐up. Fifty‐five participants (3.3%) had known post‐treatment relapse. Fifty‐four were not taking an MS DMT when they relapsed; one relapsed soon after starting fingolimod. Relapses were associated with Expanded Disability Status Scale (EDSS) score increases of 0–3 points (median 1 point); the participant with the 3‐point increase had a moderate relapse and complete recovery in 23 days. Forty‐two participants (76.4%) fully recovered, 11 (20.0%) partially recovered, and 2 (3.6%) did not recover. Only one (1.8%) relapse was considered severe by the investigator: EDSS increased from 7.5 to 8.0, and the participant partially recovered within 36 days.

Interpretation

Most participants did not relapse within 90 days following ozanimod discontinuation. Post‐treatment relapse cases suggestive of a rebound effect were not observed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IndansMultiple Sclerosis, Relapsing-RemittingOxadiazolesSphingosine 1 Phosphate Receptor ModulatorsAdultFemaleHumansMaleMiddle AgedRecurrenceTreatment Interruption

Stichwörter der Autor:innen

discontinuationdisease‐modifying therapymultiple sclerosisozanimodreboundrelapse

Substanzen

IndansOxadiazolesozanimodSphingosine 1 Phosphate Receptor Modulators

Autor:innen und Institutionen

  • Neurologische Universitätsklinik, St. Josef Hospital, Bochum, Germany.
  • Center of Neurology, Lodz, Poland.
  • Department of Neurology, University of Warmia & Mazury, Olsztyn, Poland.
  • Medical Imaging Center of Southern California, Santa Monica, California, USA.
  • Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, Ohio, USA.
  • Vita-Salute San Raffaele University and Casa di Cura Igea, Milan, Italy.

ORCID-Profile: Krzysztof W Selmaj, Bruce A C Cree

Förderung

  • Bristol Myers Squibb
  • Bristol-Myers Squibb Canada

Zitieren

APA

Gold, R., Selmaj, K. W., Berkovich, R., Cohen, J. A., Comi, G., Havrdová, E. K., Sheffield, J. K., Desai, H., Cheng, C. Y., Riolo, J. V., Thorpe, A., DeBoer, E., & Cree, B. A. C. (2026). Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.70366

Vancouver

Gold R, Selmaj KW, Berkovich R, Cohen JA, Comi G, Havrdová EK, et al. Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants. Annals of Clinical and Translational Neurology. 2026. doi:10.1002/acn3.70366

BibTeX
@article{Gold2026,
  author = {Gold, Ralf and Selmaj, Krzysztof W and Berkovich, Regina and Cohen, Jeffrey A and Comi, Giancarlo and Havrdová, Eva K and Sheffield, James K and Desai, Hetal and Cheng, Chun-Yen and Riolo, Jon V and Thorpe, Andrew and DeBoer, Erik and Cree, Bruce A C},
  title = {Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2026},
  doi = {10.1002/acn3.70366}
}
Kostenlos starten →